Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Akero Therapeutics Inc
AKROCurrent price
28.12 USD
-0.53 USD (-1.85%)
Last closed
26.82 USD
Company
www.akerotx.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 850 480 768 USD
Yield for 12 month
-31.73 %
1Y
3Y
5Y
10Y
15Y
AKRO
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
45.78 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
+284 000 USD
Current Year
-29 000 USD
Last Year
-260 000 USD
Current Quarter
-1 000 USD
Last Quarter
+282 000 USD
Key Figures AKRO
1 year
3 years
5 years
10 years
EBITDA
-204 052 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-20.23 %
PEG Ratio
–
Return On Equity TTM
-31.11 %
Wall Street Target Price
45.78 USD
Revenue TTM
–
Book Value
12.24 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-3.24 USD
Diluted Eps TTM
-3.24 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics AKRO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History AKRO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation AKRO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-6.7701
Price Book MRQ
2.8581
Financials AKRO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators AKRO
For 52 weeks
11.25 USD
53.77 USD
50 Day MA
22.26 USD
Shares Short Prior Month
7 304 150
200 Day MA
21.22 USD
Short Ratio
6.27
Shares Short
6 467 326
Short Percent
9.63 %
BeatStart